From: A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer
Toxicity endpoint
Group I
Group II
Leucopenia (grade 1-4)
3 (19%)
4 (27%)
All hematologic (grade 3-4)
2 (12%)
1 (7%)
Neurologic (grade I)
0
Diarrhea (grade 3-4)
6 (37%)
8 (53%)
Allergic reactions
1 (6%)
6 (40%)
Delay in CT
4 (25%)
7 (47%)